UNSPSC 51171968: Tiquinamide

This classification denotes an anti-ulcer agent with the molecular formula C11H14N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 51O951X8V9, chemically known as 5,6,7,8-tetrahydro-3-methyl-8-quinolinecarbothioamide but generally known as tiquinamide, which bears US NIH Compound Identifier 3003921. European Medicines Agency schedules Tiquinamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11112MIG.

UNSPSC 51171968 Tiquinamide (Commodity) covers pharmaceutical products purchased by state and local jurisdictions, though recent opportunities show activity centered on specimen collection and drug-testing services, generic multi-source pharmaceuticals and OTC products supplied through authorized wholesalers, and exploratory procurement for direct-to-manufacturer prescription programs. The code sees solicitation from state health and human services agencies, county criminal justice departments, and cooperative purchasing alliances serving multi-state and multi-jurisdiction networks. Work scoped under the code ranges from contract manufacturing and supply of pharmaceuticals with specific NDC codes and compliance certifications (cGMP, DSCSA, FDA) to operational services combining laboratory testing, specimen collection, and result reporting for offender drug screening programs.

Recent opportunities span Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 (response due July 23, 2026) for offender specimen collection and drug testing services, including staffing two sites in Plano and McKinney, immunoassay screening with LC/MS/MS or GC/MS confirmation, and alternative testing methodologies, with an estimated contract value of $600,000 over two years plus three optional one-year renewals and an anticipated award date of August 10, 2026. The Minnesota Department of Administration, on behalf of the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026 (response due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products supplied through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) to participating state and local facilities across Minnesota and Oregon, with contract effectiveness set for July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on March 27, 2026 (response deadline April 3, 2026) as preliminary market research for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, soliciting vendor capabilities for direct contracting with self-insured health plans and state agencies outside traditional PBM and GPO arrangements.